Evidence map›Paper›PMID 26002977›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Cutting Edge: Codeletion of the Ras GTPase-Activating Proteins (RasGAPs) Neurofibromin 1 and p120 RasGAP in T Cells Results in the Development of T Cell Acute Lymphoblastic Leukemia.

Beth A Lubeck, Philip E Lapinski, Jennifer A Oliver, Olga Ksionda, Luis F Parada, Yuan Zhu, Ivan Maillard, Mark Chiang, Jeroen Roose, Philip D King

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Regulation of the Small GTPase Ras and Its Relevance to Human Disease.Methods in molecular biology (Clifton, N.J.) · 2021
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  9. Article
  10. Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2017
    Review
  11. CTNNDJournal of clinical laboratory analysis · 2017
    Article
  12. Article
  13. RASopathy Gene Mutations in Melanoma.The Journal of investigative dermatology · 2016
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Beth A LubeckDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109;
Philip E LapinskiDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109;
Jennifer A OliverDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109;
Olga KsiondaDepartment of Anatomy, University of California, San Francisco, San Francisco, CA 94143;
Luis F ParadaDepartment of Developmental Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390;
Yuan ZhuDivision of Molecular Medicine and Genetics, University of Michigan Medical School, Ann Arbor, MI 48109; and.
Ivan MaillardDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109.
Mark ChiangDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48109.
Jeroen RooseDepartment of Anatomy, University of California, San Francisco, San Francisco, CA 94143;
Philip D KingDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109; kingp@umich.edu.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
RESEARCH TRAINING IN EXPERIMENTAL IMMUNOPATHOLOGYT32AI007413 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 1993 to 2026
$9.8M
Notch Signaling in AlloimmunityR01AI091627 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI PEAR, WARREN S · 2011 to 2025
$6.0M
Molecular understanding of leukemic bone marrow cytokine-Ras signals and metabolic dependenceR01CA187318 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEROEN ROOSE · 2015 to 2026
$3.6M
RASA1-mediated control of lymphatic vessel growth and functionR01HL096498 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KING, PHILIP D · 2009 to 2012
$1.4M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA187318NHLBI NIH HHS R01 HL096498NIAID NIH HHS R01 AI091627NIAID NIH HHS T32 AI007413NIAID NIH HHS T32 AI007431
6 · The paper itself

Abstract

Ras GTPase-activating proteins (RasGAPs) inhibit signal transduction initiated through the Ras small GTP-binding protein. However, which members of the RasGAP family act as negative regulators of T cell responses is not completely understood. In this study, we investigated potential roles for the RasGAPs RASA1 and neurofibromin 1 (NF1) in T cells through the generation and analysis of T cell-specific RASA1 and NF1 double-deficient mice. In contrast to mice lacking either RasGAP alone in T cells, double-deficient mice developed T cell acute lymphoblastic leukemia/lymphoma, which originated at an early point in T cell development and was dependent on activating mutations in the Notch1 gene. These findings highlight RASA1 and NF1 as cotumor suppressors in the T cell lineage.

Indexed as

AnimalsGene DeletionGene Expression RegulationMiceMice, KnockoutMutationNeurofibromin 1p120 GTPase Activating ProteinPrecursor Cell Lymphoblastic Leukemia-LymphomaReceptor, Notch1Signal TransductionSpleenSurvival AnalysisThymus GlandTime FactorsT-LymphocytesNeurofibromin 1Notch1 protein, mousep120 GTPase Activating ProteinRASA1 protein, mouseReceptor, Notch1

Identifiers

PMID26002977
PMCPMC4475412

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.